WASHINGTON, Aug. 25, 2016 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that
Judge Gregory M. Sleet of the United
States District Court for the District of Delaware ruled that Roxane Laboratories Inc.
(Roxane) infringed U.S. Patent Nos. RE39,198 (the '198 Patent) and
8,586,610 (the '610 Patent) by submitting to the FDA an ANDA
seeking permission to market a generic version of
Fanapt® before the expiration of Vanda's
patents.
"We are very pleased that the court found both patents valid,
found that Roxane's ANDA infringes the '198 patent and the '610
patent, and accordingly issued an injunction barring Roxane from
marketing its product until the expiration of the later expiring
'610 patent on November 2, 2027,"
said Mihael H. Polymeropoulos, M.D.,
Vanda's President and CEO.
About Vanda Pharmaceuticals Inc.
Vanda is a
specialty pharmaceutical company focused on the development and
commercialization of novel therapies to address high unmet medical
needs and improve the lives of patients. For more
on Vanda Pharmaceuticals, please
visit www.vandapharma.com.
Fanapt® is a registered trademark
of Vanda Pharmaceuticals Inc.
Corporate Contact:
Jim Kelly
Senior Vice
President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Group Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vanda-patents-found-valid-and-infringed-in-fanapt-anda-litigation-300318458.html
SOURCE Vanda Pharmaceuticals Inc.